We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Test Improves Risk Prediction for Open-Angle Glaucoma

By LabMedica International staff writers
Posted on 19 Nov 2026

Glaucoma damages the optic nerve and is the leading cause of irreversible blindness worldwide. Because the disease often causes no early symptoms, about half of affected individuals remain undiagnosed even in countries with good access to eye care. Since vision loss cannot be reversed once it occurs, identifying people at higher risk before significant damage develops remains a major diagnostic challenge.

Researchers at QIMR Berghofer Medical Research Institute and Flinders University, working with international collaborators, developed the new genetic test to assess risk for open-angle glaucoma, the most common form of the disease. Findings published in Ophthalmology show that the test improves on an earlier version and may help identify people at elevated risk before significant vision loss occurs.


Image: Among Australians of European ancestry, people in the highest 10% of genetic risk were 10 times more likely to have glaucoma than those outside this group. (Image Credit: Adobe Stock)
Image: Among Australians of European ancestry, people in the highest 10% of genetic risk were 10 times more likely to have glaucoma than those outside this group. (Image Credit: Adobe Stock)

The test uses a polygenic risk score that combines the effects of millions of genetic variations into a single measure of inherited risk. Researchers developed the score using genetic data from more than six million people, including nearly 300,000 individuals with glaucoma. By comparison, the previous version, published in 2020, was based on approximately 8,000 glaucoma cases.

Among Australians of European ancestry, people in the highest 10% of genetic risk were 10 times more likely to have glaucoma than those outside this group. They also developed glaucoma approximately 25 years earlier, on average, than individuals in the lowest 10% of genetic risk. In a long-term study of people with suspected or early glaucoma, 24% of those in the highest-risk group required glaucoma surgery by age 80, compared with none in the lowest-risk group.

The score also helped predict disease severity, the need for more intensive treatment, and the likelihood of glaucoma among family members. It provided additional predictive information beyond eye pressure measurements, which the researchers identify as the most commonly assessed glaucoma risk factor. 

The score was evaluated in people of European, African, East Asian, South Asian, and Hispanic ancestry, with the strongest performance observed in those of European ancestry. Further research is needed to assess the cost-effectiveness of incorporating the test into targeted glaucoma screening programs.

“In Australians of European ancestry, people in the highest 10% of genetic risk were 10 times more likely to have glaucoma than everyone else. Our earlier test identified about a fourfold increase in risk. To our knowledge, this is the strongest genetic risk prediction reported for any common complex disease,” said Stuart MacGregor, lead researcher and head of QIMR Berghofer's Statistical Genetics Laboratory. 

“Most of the large genetic data sets available today come from people of European ancestry. Improving accuracy for all populations is an important priority for our next phase of work,” added MacGregor.

Related Links
QIMR Berghofer Medical Research Institute
Flinders University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.

Latest Molecular Diagnostics News

Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
19 Nov 2026  |   Molecular Diagnostics

Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
19 Nov 2026  |   Molecular Diagnostics

Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
19 Nov 2026  |   Molecular Diagnostics